Born in Edinburgh, but growing up and schooled in South Oxfordshire, I did initial medical training at Oxford (Corpus Christi College) and Edinburgh Universities, followed by registrar training as an ACF/ACL in Cambridge from 2007 – 2016. During this time, I did my PhD with Professor David Neal on the molecular genetics of prostate cancer at the CRUK Cambridge Institute. I undertook specialty fellowship training with Associate Professor Declan Murphy at Peter MacCallum Cancer Centre in Melbourne, Australia 2016-2017 before appointment by Professor Freddie Hamdy to an academic consultant post in Oxford.
MA(Oxon) MBChB PhD FRCS(Urol)
Robotic Surgery Fellow and Academic Clinical Lecturer
My research goal is to provide a robust molecular platform for accurate decision-making in early stage prostate cancer.
I have spent my scientific training investigating how individual genes or groups of genes have driven prostate cancer behaviour. My PhD thesis investigated the role of HES6 as a transcriptional driver in castrate resistant prostate cancer – we found that this single gene fundamentally changed the nature of prostate cancer cells. During this time I was funded by the Cambridge Biomedical Research Centre (NIHR) and GlaxoSmithKline, and also by a Raymond and Beverly Sackler Studentship. Since then, I have been employing integrative genomics in prostate cancer risk stratification as well as disease modelling with patient derived xenografts.
I also have an interest in novel molecular imaging techniques such as 68Ga-PSMA PET/CT and their use in disease stratification and selection of patients for surgery.
Mortality Among Men with Advanced Prostate Cancer Excluded from the ProtecT Trial.
Johnston TJ. et al, (2017), Eur Urol, 71, 381 - 388
Corrigendum to "Integration of Copy Number and Transcriptomics Provides Risk Stratification in Prostate Cancer: A Discovery and Validation Cohort Study" [EBioMedicine 2 (9) (2015) 1133-1144].
Ross-Adams H. et al, (2017), EBioMedicine, 17
Patient-reported outcomes in the ProtecT randomized trial of clinically localized prostate cancer treatments: study design, and baseline urinary, bowel and sexual function and quality of life.
Lane A. et al, (2016), BJU Int, 118, 869 - 879
Evolution and oncological outcomes of a contemporary radical prostatectomy practice in a UK regional tertiary referral centre.
Gnanapragasam VJ. et al, (2016), BJU Int, 118, 779 - 784
The Early Effects of Rapid Androgen Deprivation on Human Prostate Cancer.
Shaw GL. et al, (2016), Eur Urol, 70, 214 - 218